Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 10, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - February 10, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/10/16 - "Bicyclic Analgesic Compounds" in Patent Application Approval Process (USPTO 20160016892)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor Bunker, Kevin Duane, filed on March 6, 2014, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Kalyra Pharmaceuticals, Inc.. The foll
2/10/16 - "Pharmaceutical Composition for Preparing Drug Delivery Nano/Micro Bubbles" in Patent Application Approval Process (USPTO 20160015629)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors SUNG, Hsing-Wen; CHUANG, Er-Yuan; LIN, Po-Yen, filed on December 1, 2014, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned t
2/10/16 - "Phenylephrine Formulations with Improved Stability" in Patent Application Approval Process (USPTO 20160015815)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors DUNGAN, Timothy; WARRINGTON, Brian, filed on May 29, 2015, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Novartis AG. The follow
2/10/16 - "Tetrahydrocannabivarin (Thcv) for Use in the Protection of Pancreatic Islet Cells" in Patent Application Approval Process (USPTO 20160015682)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Cawthorne, Michael; Stott, Colin; Wright, Stephen, filed on November 20, 2012, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to GW
2/10/16 - "Transdermal Estrogen Device and Delivery" in Patent Application Approval Process (USPTO 20160015655)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor Mantelle, Juan, filed on September 30, 2015, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Noven Pharmaceuticals, Inc.. The follo
2/10/16 - Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies
By a News Reporter-Staff News Editor at Biotech Week Adicet Bio, Inc., a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced that it closed a $51 million Series A financing. Previously, Dr. Jakobovits served as the President and founding CEO of Kite Pharma, Inc. Before joining Kite Pharma, she s
2/10/16 - Agilis Biotherapeutics Names Former Lundbeck Executive, Christopher J. Silber, MD, as Chief Medical Officer
Prior to joining Agilis, he spent seven years at H. Lundbeck A/S, a company specializing in brain disease, in senior management positions, including most recently Vice President US Clinical Development Center. Mark Pykett, President and CEO of Agilis. "I am thrilled to join Agilis at this exciting stage of the Company's growth," stated Dr. Silber.
2/10/16 - Amplyx Pharma Raises Additional USD8.7 Million in Series B Financing
Deal Type: Venture Financing Deal Sub Type: Start Up Deal Country: United States of America Deal Status: Completed Deal Value: 8.7000 USD. Amplyx Pharmaceuticals Inc., a pharmaceutical company, has raised additional USD8.7 million in series B venture financing round, bringing the total proceeds to USD49.2 million. 3 x5 Partners participated in the
2/10/16 - Array Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jan. 22, 2016)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on January 22, 2016. The SEC file number is 0000919574-16-009564.. A U.S. Securities and Exchange Commission filing is a form
2/10/16 - Array Biopharma Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals [Amend] (Jan. 25, 2016)
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on January 25, 2016. The SEC file number is 0000215457-16-002059.. A U.S. Securities and Exchange Commission filing is a form
2/10/16 - Avanir Pharmaceuticals Announces FDA Approval of ONZETRA Xsail AVP-825 for the Acute Treatment of Migraine in Adults
By a News Reporter-Staff News Editor at Biotech Week Avanir Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved ONZETRA? Xsail?, formerly known as AVP-825, for the acute treatment of migraine with or without aura in adults. Given this high dissatisfaction, there remains an unmet need to provide patients wit
2/10/16 - BLPH Heartened, More Trouble For CTIC, Remicade Biosimilar Gets FDA Panel Nod
NEW BRUNSWICK- Axovant Sciences Ltd. expects results from a phase II study of Nelotanserin in Lewy body dementia subjects experiencing visual hallucinations in the second half of calendar year 2016.. AXON closed Tuesday's trading at $10.07, up 5.89%. Shares of Bellerophon Therapeutics Inc. surged more than 43% on Tuesday, following positive data fr
2/10/16 - BPC Statement on FDA Arthritis Advisory Committee Meeting
WASHINGTON, Feb. 9, 2016/ PRNewswire-USNewswire/ On Tuesday, February 9th, the U.S. Food and Drug Administration met with its Arthritis Advisory Committee to discuss Celltrion's Remsima, a proposed biosimilar of Johnson& Johnson's Remicade and most likely the second biosimilar to be approved in the U.S. The Biologics Prescribers Collaborative alo
2/10/16 - Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO...
Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO ixazomib. By a News Reporter-Staff News Editor at Biotech Week Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples...
2/10/16 - Catabasis Pharmaceuticals Announces Positive Top-Line Results from Part A of the MoveDMD? Trial, a Phase 1 / 2 Trial of CAT-1004 for the Treatment of...
Catabasis Pharmaceuticals Announces Positive Top-Line Results from Part A of the MoveDMD? Trial, a Phase 1/ 2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy. By a News Reporter-Staff News Editor at Biotech Week Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology
2/10/16 - Catalyst Pharmaceutical Partners, New York University, Feinstein Institute for Medical Research Assigned Patent
ALEXANDRIA, Va., Feb. 10 Catalyst Pharmaceutical Partners, Coral Gables, Florida, New York University, New York, and Feinstein Institute for Medical Research, Manhasset, New York, have been assigned a patent developed by three co-inventors for a "method of treating Tourette'S disorder with GABA-aminotransferase inactivators." The co-inventors are
2/10/16 - CheckMate -141, a Pivotal Phase 3 Opdivo nivolumab Head and Neck Cancer Trial, Stopped Early
By a News Reporter-Staff News Editor at Biotech Week Bristol-Myers Squibb Company announced that a randomized Phase 3 study evaluating Opdivo versus investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck was stopped early because an assessment conducted by the independent...
2/10/16 - Cipla, Ambuja Cement, Kalpataru Power and GMR Infra: Check out the expectations [India Infoline News Service]
IIFL forecasts the company's net revenue for Q3 FY16 to increase to Rs. 3,403 crore, growing at a rate of 23.1% yoy; however, it is likely to drop 1.4% qoq. GlaxoSmithKline Pharmaceuticals Ltd, one of the leading pharma companies in India, will announce its Q3 numbers today. IIFL forecasts the company's net revenue for Q3 FY16 to plummet to Rs. 620
2/10/16 - Clinical trials enable medical breakthroughs
Frederick Schaerf, M.D., psychiatrist, principal investigator and founder of the center, established a clinical trial program to provide access to leading-edge research for the citizens of Southwest Florida. The work Dr. Schaerf, his team and his clinical trial participants are doing is changing the future of this devastating disease. As part of th
2/10/16 - CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S.
Following the issuance of the Company's February 8, 2016, press release describing the partial clinical hold issued by the U.S. Food and Drug Administration regarding those clinical studies, the Company received an oral communication from the FDA followed by a letter notifying the Company that the Company's IND for pacritinib has been placed on ful
2/10/16 - CTI BioPharma Withdraws Pacritinib NDA As FDA Places Full Clinical Hold
WASHINGTON- CTI BioPharma Corp. said that it has withdrawn its New Drug Application for pacritinib as the FDA has revised the partial clinical hold imposed on February 8, 2016 to full clinical hold. The FDA made recommendations that supersede the recommendations made by the FDA in connection with the partial clinical hold imposed by the FDA on Febr
2/10/16 - Current and Future Trends for Big Data Utilization in the Pharmaceutical Industry
By a News Reporter-Staff News Editor at Biotech Week The rapid evolution of Big Data is generating greater insights for pharmaceutical companies. At the same time, organizations are encountering challenges in building strong analytical Big Data teams and forming critical data partnerships. Now, more than ever, it is critical for organizations to.
2/10/16 - EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion
By a News Reporter-Staff News Editor at Biotech Week EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV? nanocell platform for the targeted delivery of cancer therapeutics, announced the appointment of Edward D. Miller, M.D., and Yvonne Perlberg, M.A., C.P.A., to the Company's Board of Directors.
2/10/16 - Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced...
By a News Reporter-Staff News Editor at Biotech Week Exelixis, Inc. announced that the U.S. Food& Drug Administration has determined the company's New Drug Application for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy to be sufficiently complete to permit a substantive review.
2/10/16 - FDA approves Adaptimmune Therapeutics 'breakthrough' cancer treatment [The Philadelphia Inquirer]
Feb. 10 Adaptimmune Therapeutics, a biopharmaceutical company with U.S. operations in Philadelphia, said Tuesdaythe Food and Drug Administration has granted "breakthrough therapy designation" for its TCR engineered T-cell therapy to treat cancer. Adaptimmune, which has a collaboration and licensing agreement with GlaxoSmithKline to commercialize
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415